What Latent Labs does
Latent Labs is an AI-for-science company focused on making protein and biological molecule design more controllable and faster by combining frontier generative models with wet-lab validation. The company positions its work as “programmable biology,” with products aimed at helping researchers and biopharma teams generate therapeutic biomolecules such as antibodies, nanobodies, and macrocyclic peptides, and—more recently—run agentic design workflows that translate high-level prompts into lab-ready sequences.
Latent Labs’ primary customer surface is the Latent Labs Platform, which provides web-based, no-code access to its model family for protein binder design and (for agentic workflows) structured end-to-end campaigns. The company also describes deploying models in customer environments via APIs for commercial use cases (particularly for partner access and scaling within drug-discovery pipelines). In its public-facing materials, Latent Labs emphasizes that it experimentally validates model outputs in-house lab facilities in San Francisco and uses partner programs to iterate toward higher success rates and improved molecule properties.
Strategically, Latent Labs is moving along a model-to-workflow trajectory: (1) Latent-X provides atom-level de novo protein binder design with laboratory-validation claims for macrocycles and mini-binders; (2) Latent-X2 extends toward drug-like biologics (notably antibodies and peptides) with claimed zero-shot generation and developability/immunogenicity proxy testing; and (3) Latent-Y wraps Latent-X2 into an autonomous agent workflow that handles the multi-step research/design process (target analysis through candidate generation and selection), with Latent-Y becoming accessible via a “Research Tier” for broader researcher access.